
The global pharmaceutical industry continues to experience strong growth driven by innovation in biologics, oncology, diabetes and obesity treatment, vaccines, and rare disease therapies. In August 2026, Pharm Exec magazine published the 2026 Pharm Exec 50, ranking the Top 50 pharmaceutical companies worldwide by prescription drug (Rx) sales in fiscal year 2025.
This ranking is widely regarded as one of the most authoritative industry benchmarks, offering valuable insight for pharmaceutical manufacturers, API and packaging suppliers, pharmaceutical equipment companies, and distributors and contract manufacturing organizations (CMOs).
Below is the fully updated 2026 Global Top 50 Pharmaceutical Companies List, based on 2025 Rx sales.
Table des matières
BasculerCe classement reflète une réelle performance commerciale, not market capitalization or valuation. Figures in the table are 2025 Rx sales, shown in US$ billion.
| Rang | Entreprise | Quartier général | 2025 Rx sales (US$ billion) |
|---|---|---|---|
| 1 | Elie Lilly | USA | 60.78 |
| 2 | Johnson & Johnson | USA | 59.33 |
| 3 | AbbVie | USA | 58.27 |
| 4 | Roche | Suisse | 57.51 |
| 5 | AstraZeneca | ROYAUME-UNI | 55.04 |
| 6 | Merck & Co. (MSD) | USA | 54.69 |
| 7 | Novartis | Suisse | 54.33 |
| 8 | Pfizer | USA | 49.91 |
| 9 | Sanofi | France | 48.97 |
| 10 | Bristol Myers Squibb | USA | 47.75 |
| 11 | Novo Nordisk | Danemark | 46.80 |
| 12 | GSK (GlaxoSmithKline) | ROYAUME-UNI | 42.72 |
| 13 | Amgen | USA | 34.95 |
| 14 | Takeda | Japon | 29.67 |
| 15 | Sciences de Galaad | USA | 28.83 |
| 16 | Boehringer Ingelheim | Allemagne | 23.82 |
| 17 | Bayer | Allemagne | 19.19 |
| 18 | CSL | Australie | 15.44 |
| 19 | Viatris | USA | 14.09 |
| 20 | Téva | Israël | 14.08 |
| 21 | Astellas | Japon | 12.60 |
| 22 | Daiichi Sankyo | Japon | 12.04 |
| 23 | Produits pharmaceutiques Vertex | USA | 11.97 |
| 24 | Groupe Sandoz | Suisse | 11.09 |
| 25 | Otsuka Holdings | Japon | 9.87 |
| 26 | Merck KGaA | Allemagne | 9.73 |
| 27 | UCB | Belgique | 8.24 |
| 28 | Grifols | Espagne | 7.33 |
| 29 | Biogène | USA | 7.12 |
| 30 | Sun Pharma | Inde | 6.44 |
| 31 | Régénéron | USA | 6.31 |
| 32 | Organon | USA | 6.06 |
| 33 | Yunnan Baiyao | Chine | 5.72 |
| 34 | Abbott | USA | 5.51 |
| 35 | Servier | France | 5.44 |
| 36 | Bausch Health | Canada | 5.41 |
| 37 | BeOne Medicines (formerly BeiGene) | Suisse | 5.28 |
| 38 | Fresenius | Allemagne | 5.21 |
| 39 | Shanghai Pharmaceuticals | Chine | 5.16 |
| 40 | Eisaï | Japon | 4.78 |
| 41 | Sino Biopharmaceutical | Hong Kong | 4.37 |
| 42 | Ménarini | Italie | 4.36 |
| 43 | Incyte | USA | 4.35 |
| 44 | Ipsen | France | 4.16 |
| 45 | argenx | Pays-Bas | 4.15 |
| 46 | Jazz Pharmaceutique | Irlande | 4.02 |
| 47 | STADA | Allemagne | 4.02 |
| 48 | Médecine Huadong | Chine | 3.97 |
| 49 | Médecine Jiangsu Hengrui | Chine | 3.85 |
| 50 | Haleon | ROYAUME-UNI | 3.60 |
Data source: Pharm Exec, 2026 Pharm Exec 50 (FY 2025 prescription drug sales). Company names use common English forms; BeOne Medicines appears under its current name (formerly BeiGene).
The headline change this year is Eli Lilly’s jump from No. 11 in the previous ranking to No. 1, with about $60.8 billion in 2025 Rx sales, up roughly 49% year over year. Johnson & Johnson, last year’s leader, is now No. 2. AbbVie, Roche, and AstraZeneca complete the top five.
Fifteen companies in the Top 50 are headquartered in the United States, still the largest national group, with particular strength in oncology, immunology, biologics, and metabolic disease, including GLP-1 therapies.
Switzerland is represented by Roche, Novartis, Sandoz, and BeOne Medicines (formerly BeiGene, now listed with a Swiss headquarters). Japan remains well represented by Takeda, Astellas, Daiichi Sankyo, Otsuka, and Eisai. Germany includes Boehringer Ingelheim, Bayer, Merck KGaA, Fresenius, and STADA.
Five Chinese companies are in this year’s list if Sino Biopharmaceutical (Hong Kong) is included: Yunnan Baiyao, Shanghai Pharmaceuticals (a new entrant), Sino Biopharmaceutical, Huadong Medicine, and Jiangsu Hengrui Medicine. CSPC Pharmaceutical Group is no longer in the Top 50. From India, Sun Pharma remains on the list; Dr. Reddy’s Laboratories is not in this year’s Top 50. New global entrants also include argenx (Netherlands) and Haleon (UK).
If you are involved in pharmaceutical machinery manufacturing, packaging solutions (vials, bottles, blister, ampoules), API and excipient supply, or contract manufacturing (CDMO/CMO), this list directly reflects where purchasing power is concentrated, which companies control global drug production, and who your most valuable long-term customers may be.
Based on this ranking, the pharmaceutical industry will continue focusing on biologics and biosimilars, GLP-1 diabetes and obesity drugs, cancer immunotherapy, rare disease treatments, and personalized medicine. Companies at the top of the 2026 Pharm Exec 50 are expected to drive mergers and acquisitions, equipment upgrades, and new plant investments worldwide.
La plupart des entreprises de ce classement mènent de grandes opérations de dosage oral solide (OSD) parallèlement aux produits biologiques. Leurs usines de comprimés et de capsules sont construites autour d'une chaîne de processus similaire, et chaque étape nécessite un équipement de qualité GMP qui produit des lots reproductibles. Nous couvrons cela en détail dans quel équipement les 50 plus grandes sociétés pharmaceutiques mondiales utilisent-elles pour garantir la qualité.
| Étape du processus | But | Équipements JIANPAI associés |
|---|---|---|
| Granulation humide | Densifier les poudres et améliorer l’uniformité du flux et du contenu | Granulateurs mélangeurs à haut cisaillement (JHZ-C, JHZ-D) |
| Séchage | Réduire l'humidité des granulés au niveau validé | Sécheurs à lit fluidisé (JFG-C) |
| Dimensionnement et fraisage | Contrôler la taille des particules avant de mélanger | Usines pharmaceutiques (Granulateur de dimensionnement JZL) |
| Mélange | Mélanger les granulés avec des lubrifiants et des excipients | Mélangeurs pharmaceutiques (Mélangeur à trois excentricités JPH) |
| Revêtement | Film, sucre ou enrobage entérique des comprimés | Machines à enrober les comprimés (JGB-D, JGB-E) |
| Lignes intégrées | Lignes de granulation fermées et reliées qui réduisent la manipulation manuelle | Ligne de production de granulation totalement fermée, fabrication continue |
Les fabricants de génériques et sous contrat qui approvisionnent ces leaders, ou qui sont en concurrence avec eux, comparent souvent leurs propres gammes aux mêmes normes. Pour la planification budgétaire, consultez notre guide des prix des machines de revêtement de comprimés.
Le 2026 Global Top 50 Pharmaceutical Companies Ranking provides a clear overview of the world’s leading drug manufacturers, based on 2025 prescription drug sales, and reflects the direction of the global pharmaceutical industry. From biologics and oncology to diabetes, obesity, and rare disease therapies, these top companies will continue to drive innovation, capacity expansion, and equipment upgrades worldwide.
En tant que fabricant professionnel de machines pharmaceutiques, Jianpai closely follows the development trends of these global pharma leaders and is committed to providing reliable, high-efficiency production and processing solutions for pharmaceutical manufacturers across the world. Whether you are planning a new production line, upgrading existing equipment, or expanding your formulation and packaging capacity, JIANPAI offers customized solutions to meet your exact needs.
Eli Lilly is No. 1 in the 2026 Pharm Exec 50, with about $60.8 billion in 2025 prescription (Rx) drug sales. Johnson & Johnson is No. 2. The complete Top 50 table above ranks companies by 2025 Rx sales, as described in the methodology section.
Large OSD plants typically run high shear wet granulation, fluid bed drying, milling and sizing, blending, tablet compression, and film or functional coating, often with closed material transfer and automated cleaning.
Top companies set the quality and compliance expectations that generic and contract manufacturers follow. Equipment that meets their GMP, data integrity and containment needs is increasingly expected across the industry.
JIANPAI fournit des équipements de granulation, de séchage, de broyage, de mélange et d'enrobage pour les usines de dosage oral solide. Envoyez-nous vos produits et votre capacité cible pour une proposition de ligne.
E-mail: [email protected] | Tél : +86 577-86932456 | No. 989 Lingde Road, nouveau district d'Oujiangkou, Wenzhou, Zhejiang, Chine